Kamari Pharma Overview
Kamari Pharma is a biopharmaceutical company aiming to develop and commercialize proprietary small molecule inhibitors of TRPV3, a cation channel expressed primary in keratinocytes, for the treatment of dermatological conditions with unmet need. TRPV3 has been extensively evaluated as a target for drug development, identified as the cause of Olmsted syndrome in humans, and shows involvement in various skin disorders including keratoderma, atopic dermatitis, psoriasis, rosacea, and post-burn pruritus.
Cumulative Funding Raised Over Time ($)
Latest News
growth-positive
Kamari Pharma Announces Closing of $23 Million Financing to Advance its First-In-Class Oral TRPV3 Inhibitor for Rare Genetic Skin Diseases
Kamari Pharma, a clinical-stage biotechnology company, has secured $23 million in Series A financing co-led by BRM Group and Pontifax. The funds will be used to advance Kamaris lead program, KM023, an oral TRPV3 inhibitor, into clinical development for treating rare genetic skin diseases such as Olmsted syndrome, severe keratoderma, and ichthyosis. The company plans to commence a Phase 1b clinical trial for Olmsted syndrome by the end of 2025. Kamaris approach in the rare dermatology space is distinguished by its focus on TRPV3 inhibition, and the investment will accelerate the development of KM023.
InvestmentProduct Stage
growth-positive
Kamari Pharma Raises $8 Million from the Sino-Israeli GIBF2 Fund - Forbes Israel
Kamari Pharma, a clinical stage company developing drugs for dermatological diseases, has announced an $8 million investment from Chinese fund GIBF2. The company, founded by Pontifax and Arkin Bioholdings, has received a total investment of $16 million. Kamari develops drugs based on proprietary small molecules for the treatment of various dermatological diseases. The investment will allow Kamari to continue promoting its clinical programs and expand its clinical trials by collaborating with leading hospitals in China. GIBF2, a Chinese investment fund, focuses on Western biotechnology companies in phase 2-3 of clinical trials. The fund aims to develop innovative activity in China and build value in the Chinese market.
Investment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $31M |
| Last funding | $23M |
| Stage | A |
| Rounds | 3 |
| Investors | 4 |
Team Members
3
Employees: 1-10
Web & Social Links
| Website | kamaripharma.com/ |
Locations
Pinhas Sapir Street 3, Ness Ziona, Israel
Photos & Videos
No files yet
